Anifrolumab-fnia

Anifrolumab-fnia
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Tejasvi Aryaputra

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Anifrolumab-fnia is a type I interferon receptor antagonist that is FDA approved for the treatment of moderate-to severe systemic lupus erythematousus along with standard therapy. Common adverse reactions include bronchitis, nasopharyngitis, herpes zoster, upper respiratory tract infections, infusion related reactions, and cough.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Anifrolumab-fnia FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Anifrolumab-fnia in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Anifrolumab-fnia in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Anifrolumab-fnia FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Anifrolumab-fnia in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Anifrolumab-fnia in pediatric patients.

Contraindications

There is limited information regarding Anifrolumab-fnia Contraindications in the drug label.

Warnings

There is limited information regarding Anifrolumab-fnia Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Anifrolumab-fnia Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Anifrolumab-fnia Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Anifrolumab-fnia Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Anifrolumab-fnia in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Anifrolumab-fnia in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Anifrolumab-fnia during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Anifrolumab-fnia in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Anifrolumab-fnia in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Anifrolumab-fnia in geriatric settings.

Gender

There is no FDA guidance on the use of Anifrolumab-fnia with respect to specific gender populations.

Race

There is no FDA guidance on the use of Anifrolumab-fnia with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Anifrolumab-fnia in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Anifrolumab-fnia in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Anifrolumab-fnia in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Anifrolumab-fnia in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Anifrolumab-fnia Administration in the drug label.

Monitoring

There is limited information regarding Anifrolumab-fnia Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Anifrolumab-fnia and IV administrations.

Overdosage

There is limited information regarding Anifrolumab-fnia overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Anifrolumab-fnia Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Anifrolumab-fnia Mechanism of Action in the drug label.

Structure

There is limited information regarding Anifrolumab-fnia Structure in the drug label.

Pharmacodynamics

There is limited information regarding Anifrolumab-fnia Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Anifrolumab-fnia Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Anifrolumab-fnia Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Anifrolumab-fnia Clinical Studies in the drug label.

How Supplied

There is limited information regarding Anifrolumab-fnia How Supplied in the drug label.

Storage

There is limited information regarding Anifrolumab-fnia Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Anifrolumab-fnia |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Anifrolumab-fnia |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Anifrolumab-fnia Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Anifrolumab-fnia interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Anifrolumab-fnia Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Anifrolumab-fnia Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.